Amanote Research
Register
Sign In
Pnd71 - A Cost Minimisation Analysis of Cladribine Tablets Versus Alternative High Efficacy Treatments for Relapsing Multiple Sclerosis (Rms) in the Unied Kingdom.
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2037
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
G Harty
C Treharne
S Budhia
SL Wong
Publisher
Elsevier BV
Related search
Pnd28 - A Budget Impact Analysis of Cladribine Tablets Versus Alternative High Efficacy Treatments for Relapsing Multiple Sclerosis (Rms) in the United Kingdom.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cladribine for Highly Active Relapsing Multiple Sclerosis
Prescriber
Pharmacology
Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics
Health Policy
Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
Advances in Therapy
Medicine
Pharmacology
Pnd63 - Cost-Effectiveness of Cladribine Tablets and Fingolimod in the Treatment of Remitting Multiple Sclerosis With High Disease Activity in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Budget Impact Analysis of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remittimg Multiple Sclerosis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
